Durable response in platinum refractory small cell carcinoma of the ovary hypercalcemic type treated with combination pembrolizumab, oral cyclophosphamide, and bevacizumab
Recommended Citation
Shu MK, Moses E, Korangy E, McGrath J, and Reyes HD. Durable response in platinum refractory small cell carcinoma of the ovary hypercalcemic type treated with combination pembrolizumab, oral cyclophosphamide, and bevacizumab. Int J Gynecol Cancer 2024; 34(5):777-782.
Document Type
Article
Publication Date
5-6-2024
Publication Title
International journal of gynecological cancer
Keywords
Humans, Female, Bevacizumab, Cyclophosphamide, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, Carcinoma, Small Cell, Hypercalcemia, Middle Aged
Medical Subject Headings
Humans; Female; Bevacizumab; Cyclophosphamide; Antibodies; Monoclonal; Humanized; Antineoplastic Combined Chemotherapy Protocols; Ovarian Neoplasms; Carcinoma; Small Cell; Hypercalcemia; Middle Aged
PubMed ID
38719275
Volume
34
Issue
5
First Page
777
Last Page
782
COinS
